National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Regorafenib (Stivarga®) for mCRC

Regorafenib (Stivarga®) is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.

Rapid Review

Commenced Completed Outcome
12/09/2013 02/10/2013 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 14/02/2014  30/06/2014 Reimbursement Not Recommended

The NCPE does not recommend regorafenib (Stivarga®) as a cost-effective treatment option.

Regorafenib summary report

Following discussions between the HSE and the company, regorafenib is now reimbursed under a patient access scheme.